Total submissions: 2
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Labcorp Genetics |
RCV002605069 | SCV002967014 | uncertain significance | Renal cell carcinoma | 2023-05-17 | criteria provided, single submitter | clinical testing | This sequence change replaces cysteine, which is neutral and slightly polar, with tyrosine, which is neutral and polar, at codon 95 of the MET protein (p.Cys95Tyr). This variant is not present in population databases (gnomAD no frequency). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt MET protein function. ClinVar contains an entry for this variant (Variation ID: 1926152). This variant has not been reported in the literature in individuals affected with MET-related conditions. |
| Ambry Genetics | RCV003167507 | SCV003867847 | uncertain significance | Hereditary cancer-predisposing syndrome | 2022-12-08 | criteria provided, single submitter | clinical testing | The p.C95Y variant (also known as c.284G>A), located in coding exon 1 of the MET gene, results from a G to A substitution at nucleotide position 284. The cysteine at codon 95 is replaced by tyrosine, an amino acid with highly dissimilar properties. This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |